Document is current
Any future updates will be listed below
-
Authors
Schmalzing, Marc https://orcid.org/0000-0002-3289-2299
Askari, Ayman
Girolomoni, Giampiero https://orcid.org/0000-0001-8548-0493
Perez-Coleman, Julio C. V.
Salvati, Cristofer
Bachinskaya, Elena
-
Funding
Funding for this research was provided by:
Sandoz
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 1 September 2025
First Online: 18 November 2025
Declarations
:
: Marc Schmalzing declares having received compensation for consulting from Chugai/Roche, Hexal/Sandoz, Gilead, AbbVie, Janssen-Cilag, Boehringer Ingelheim, onkowissen.de, EUSA-Pharma, Novartis, AstraZeneca, Amgen, Medac, Lilly and Galapagos; speaker’s fees from Novartis, AbbVie, AstraZeneca, Chugai/Roche, Janssen-Cilag, Gilead, Boehringer Ingelheim, Mylan, Galapagos and EUSA-Pharma; and travel grants from Chugai/Roche, Boehringer Ingelheim, Celgene, Medac, UCB, Mylan and Galapagos. Ayman Askari has no conflicts of interest to declare. Giampiero Girolomoni declares work as a consultant and/or speaker for AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol-Meyers Squibb, Eli Lilly, LEO Pharma, Novartis, Pfizer, Samsung, Sanofi and UCB. Julio C. V. Perez-Coleman declares consulting fees from Sandoz, AbbVie and Novartis. Cristofer Salvati and Elena Bachinskaya are employees of Sandoz Limited.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
